Locations:
Search IconSearch
October 18, 2023/Cancer/News & Insight

Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4274330-CQD-Hero-650×450

As new therapies and modalities are emerging for treating head and neck cancers, Cleveland Clinic Cancer Center is hosting an in-person CME program highlighting:

  • Emerging surgical techniques
  • Radiation and chemotherapy best practices
  • Recognizing and diagnosing rare head and neck cancers
  • The necessity for multidisciplinary care
  • Managing referral decisions

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The course will highlight innovative approaches to head and neck cancer treatment,” says Joseph Scharpf, MD, Director of Head and Neck Endocrine Surgery at Cleveland Clinic. “It will provide an excellent contemporary update and highlight cutting-edge treatments, which have evolved in all the specialties represented.”

The program, entitled 2023 Contemporary Multidisciplinary Care of the Head and Neck Cancer Patient: Updates on the Innovative Approaches to Head and Neck Cancer Treatment, will be held on Friday, November 17, 2023 at Cleveland Clinic Learner Research Institute. The sessions are recommended for head and neck surgeons, otolaryngologists, medical oncologists, radiation oncologists, trainees, advanced practice providers as well as speech language pathologists and nurses involved in the diagnosis and treatment of head and neck cancers.

Specialists from head and neck oncology, head and neck endocrine surgery, radiation oncology, medical oncology, speech and language pathology, oral rehabilitation surgery, dermatologic surgery, radiology, pathology and reconstructive surgery will lead the sessions. “The panels include expert faculty drawing from leaders in our field internally at Cleveland Clinic and nationally recognized guests, including an alumnus as a guest of honor,” says Dr. Scharpf.

Program highlights

Sessions will cover:

  • Advances in screening and prevention of head and neck cancer
  • Utilization of molecular and nonmolecular biomarkers in treatment decisions
  • Recent innovations in treating advanced cutaneous squamous cell carcinoma
  • Innovative approaches to improving functional and quality of life outcomes
  • Tumor board cases

Advertisement

CME credits

This live activity represents a maximum of 7.50 AM PRA category 1 credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for category 2 credit. A certificate of participation will be provided to other health care professionals for requesting credit in accordance with their professional boards and/or associations.

Session fee

$150 for physicians
$50 for allied health professionals, residents and fellows

Register now.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad